Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Subependymal giant cell astrocytoma screening
Introduction
Overview
Overview
According to the International Tuberous Sclerosis Complex Consensus, screening for subependymal giant cell astrocytoma by MRI is recommended every 1-3 years among patients with tuberous sclerosis, even in the abscence of symptoms.
Screening
Screening
According to the International Tuberous Sclerosis Complex Consensus, screening for subependymal giant cell astrocytoma by MRI is recommended every 1-3 years among patients with tuberous sclerosis, even in the abscence of symptoms.[1][2]
References
References
- β Roth, Jonathan; Roach, E. Steve; Bartels, Ute; JΓ³ΕΊwiak, Sergiusz; Koenig, Mary Kay; Weiner, Howard L.; Franz, David N.; Wang, Henry Z. (2013). “Subependymal Giant Cell Astrocytoma: Diagnosis, Screening, and Treatment. Recommendations From the International Tuberous Sclerosis Complex Consensus Conference 2012”. Pediatric Neurology. 49 (6): 439β444. doi:10.1016/j.pediatrneurol.2013.08.017. ISSNΒ 0887-8994.
- β Campen CJ, Porter BE (2011). “Subependymal Giant Cell Astrocytoma (SEGA) Treatment Update”. Curr Treat Options Neurol. 13 (4): 380β5. doi:10.1007/s11940-011-0123-z. PMCΒ 3130084. PMIDΒ 21465222.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Sujit Routray, M.D. [2], Ifeoma Odukwe, M.D. [3]